Chief Executive Officer
What I do at MMV:
As Chief Executive Officer, I am responsible for working in close collaboration with MMV’s Board of Directors and leading the Executive Management Team at MMV to develop, implement and track progress on a strategic plan that advances the mission of the organization – to discover, develop and facilitate access to new malaria medicines that will pave the way for malaria elimination and eradication.
My role also includes communicating the mission of MMV internally, to focus and motivate the organization, and externally, to maintain the confidence of our current donor and partner base and to secure new funding to support our operations.
Why I work at MMV:
We bring forward high quality, affordable medicines that save children’s lives.
MMV has established the largest portfolio of malaria drugs ever assembled – some of which are launched and saving patients’ lives today. Furthermore, the profile of molecules that MMV has in development is such that the medicines we will progress to market in the future will bring even greater benefit, further reducing death and suffering from malaria and paving the way for elimination and eradication. It’s a privilege to be part of that endeavour.
I believe that MMV’s partnership model will help us succeed in our mission.
Our success in eliminating and finally eradicating malaria lies in the hands of a highly dedicated team of MMV professionals working together with committed partners, all driven by the same goal of bringing better, affordable medicines to patients in need in malaria-endemic countries. We are strongly supported by a committed Board of Directors, Expert Advisors and engaged donors. I couldn’t have asked for a more committed group of partners to work with!
More about me:
I joined MMV in 2010. Before that, I was a Vice President at Roche, in Basel, Switzerland. My 20 years of management experience in the healthcare industry includes: successful leadership of drug development teams; licensing and alliance management; market analytics and business planning; product and disease area management; and interfacing with Governments, NGOs and patient advocacy groups in priority disease areas including HIV/AIDS and pandemic influenza.
Although my industry experience is primarily in global product strategy, I also have a scientific background. I have a doctorate in Cellular and Molecular Biology from the University of Auckland, New Zealand and completed a Post-Doctoral fellowship in molecular neurobiology at the Friedrich-Miescher Institute in Basel Switzerland.
Ask me about:
Challenging issues in developing a drug or in facilitating access to that medicine.
Partners, sources of support and funding – how to get things done.
Anything – I have an open door policy!